rinvatercept — FDA meeting
H2 2026
We also plan to engage regulators on the design of a Phase 2 clinical trial of rinvatercept in patients with ALS in the second half of 2026.Source filing
KROS biotech catalysts & pipeline
KEROS THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
rinvatercept — Topline data
H1 2027
We have initiated an open-label, multi-cohort Phase 2 basket clinical trial to evaluate rinvatercept in patients with DMD and we expect to report initial data from this trial in the first half of 2027Source filing